0.463
price up icon3.23%   0.0145
after-market 시간 외 거래: .49 0.027 +5.83%
loading
전일 마감가:
$0.4485
열려 있는:
$0.435
하루 거래량:
748.13K
Relative Volume:
1.49
시가총액:
$8.74M
수익:
-
순이익/손실:
$-16.26M
주가수익비율:
-0.3919
EPS:
-1.1814
순현금흐름:
$-13.50M
1주 성능:
-2.57%
1개월 성능:
-17.31%
6개월 성능:
-83.16%
1년 성능:
-90.70%
1일 변동 폭
Value
$0.4217
$0.58
1주일 범위
Value
$0.4217
$0.63
52주 변동 폭
Value
$0.29
$5.10

인텐시티 테라퓨틱스 Stock (INTS) Company Profile

Name
명칭
Intensity Therapeutics Inc
Name
전화
203-221-7381
Name
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Name
직원
16
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
INTS's Discussions on Twitter

INTS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
INTS
Intensity Therapeutics Inc
0.463 8.74M 0 -16.26M -13.50M -1.1814
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스

pulisher
Jun 06, 2025

Intensity Therapeutics Faces Nasdaq Delisting Notice - TipRanks

Jun 06, 2025
pulisher
Jun 03, 2025

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference - The Globe and Mail

Jun 03, 2025
pulisher
Jun 02, 2025

Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews

Jun 02, 2025
pulisher
May 29, 2025

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Morningstar

May 29, 2025
pulisher
May 28, 2025

Intratumoral Cancer Treatment Market 2034: EMA, PDMA, FDA - openPR.com

May 28, 2025
pulisher
May 28, 2025

Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon - Morningstar

May 28, 2025
pulisher
May 27, 2025

Liposarcoma Clinical Trial Analysis: Key Insights into Rich - GlobeNewswire

May 27, 2025
pulisher
May 23, 2025

Imunon Stock Price, Quotes and Forecasts | NASDAQ:IMNN - Benzinga

May 23, 2025
pulisher
May 23, 2025

Intensity Therapeutics stock hits 52-week low at $0.29 By Investing.com - Investing.com Nigeria

May 23, 2025
pulisher
May 23, 2025

Intensity Therapeutics stock hits 52-week low at $0.29 - Investing.com

May 23, 2025
pulisher
May 22, 2025

Alliance Global Partners Adjusts Price Target for Intensity Therapeutics (INTS) | INTS Stock News - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Benchmark maintains Speculative Buy on Intensity Therapeutics stock - Investing.com

May 21, 2025
pulisher
May 21, 2025

Benchmark maintains Speculative Buy on Intensity Therapeutics stock By Investing.com - Investing.com India

May 21, 2025
pulisher
May 20, 2025

Intensity Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks

May 20, 2025
pulisher
May 19, 2025

Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma - openPR.com

May 19, 2025
pulisher
May 19, 2025

Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 19, 2025
pulisher
May 19, 2025

Intra-tumoral Cancer Therapies Market to Show Tremendous Growth at a CAGR of 31.3% During the Study Period (2020-2034) | DelveInsight - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Intensity stock rating cut to Hold by Brookline Capital - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

Intensity Therapeutics (INTS) Downgraded as Funding Concerns Ari - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Brookline Capital Downgrades Intensity Therapeutics to Hold From Buy - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Intensity Therapeutics (INTS) Downgraded as Funding Concerns Arise | INTS Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Intensity Therapeutics downgraded to Hold from Buy at Brookline - TipRanks

May 19, 2025
pulisher
May 17, 2025

Intensity Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 17, 2025
pulisher
May 16, 2025

Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Nkarta (NKTX) and Kamada (KMDA) - The Globe and Mail

May 16, 2025
pulisher
May 14, 2025

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me - Quantisnow

May 14, 2025
pulisher
May 14, 2025

INTS Faces Challenges Yet Advances in Key Cancer Programs | INTS Stock News - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Health Beat: Muscle loss and cognitive function - WFMZ.com

May 13, 2025
pulisher
May 13, 2025

International Hummus Day arrives with a surge in plant-based picks - WFMZ.com

May 13, 2025
pulisher
May 13, 2025

Curious? Healthy Brain Aging Might Depend On It - WFMZ.com

May 13, 2025
pulisher
May 12, 2025

Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com

May 12, 2025
pulisher
May 10, 2025

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Reg - GuruFocus

May 10, 2025
pulisher
May 06, 2025

Intensity Therapeutics (INTS) Expands Cancer Trial to France | I - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Intensity Therapeutics (INTS) Expands Cancer Trial to France | INTS Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast - Yahoo Finance

May 06, 2025
pulisher
May 05, 2025

Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, - openPR.com

May 05, 2025
pulisher
May 05, 2025

Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com

May 05, 2025
pulisher
May 02, 2025

Offerings News Live Feed - Stock Titan

May 02, 2025
pulisher
May 02, 2025

Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds - Barchart.com

May 02, 2025
pulisher
Apr 29, 2025

Intratumoral Cancer Therapies Market Predicted to See Upsurge - openPR.com

Apr 29, 2025
pulisher
Apr 29, 2025

Post-Trade Analysis: Intensity Therapeutics Inc (INTS) Climbs 12.57, Closing at 0.64 - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Daily Market Movement: Lexeo Therapeutics Inc (LXEO) Sees a -3.53 Decrease, Closing at 3.55 - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Closing Bell Recap: Greenlane Holdings Inc (GNLN) Ends at 0.01, Reflecting a -3.23 Downturn - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

In the Green: TMD Energy Ltd (TMDE) Closes at 1.58, Up/Down 5.33 from Previous Day - DWinneX

Apr 29, 2025
pulisher
Apr 28, 2025

Navigating INTS’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com

Apr 28, 2025
pulisher
Apr 28, 2025

The Business Case For Buying Intensity Therapeutics Inc (NASDAQ: INTS) Stock Now - Stocksregister

Apr 28, 2025
pulisher
Apr 26, 2025

Intensity Therapeutics plunges on $2.35M public offering - MSN

Apr 26, 2025
pulisher
Apr 26, 2025

US Stock Futures Dip As Oil Prices Continue To Slide - Finimize

Apr 26, 2025
pulisher
Apr 26, 2025

Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail

Apr 26, 2025
pulisher
Apr 26, 2025

United States shares higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com India

Apr 26, 2025

인텐시티 테라퓨틱스 (INTS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
자본화:     |  볼륨(24시간):